Clinical Trial Update: A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for CRLX101 (NLG207) in advanced non-small cell lung cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CRLX101

Snippet

Sponsor: NewLink Genetics Corporation | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-05-24